The present study was performed to determine the histological, ultrastructu
ral, and radiographic changes that occur over time at intramuscular BMP-9 g
ene therapy treatment sites. Several members of the bone morphogenetic prot
ein (BMP) family have the potential to induce osteochondrogenesis when the
protein is delivered to rodents, canines, rabbits, and nonhuman primates. P
revious studies have also demonstrated that BMP gene therapy utilizing aden
oviral vectors can also stimulate orthotopic and heterotopic bone formation
in rodents and rabbits. Athymic nude and Sprague-Dawley rats were injected
with Ad-BMP-9 or Ad-beta -Gal (3.75 x 10(9) particles) in their thigh musc
ulature and light microscopic, electron microscopic, and computerized tomog
raphy analysis was performed 3, 6, 9, 12, 15, 18, 21, and 100 days later. T
o assess early mesenchymal cell proliferation, a bromodeoxyuridine (BrdU) i
mmunohistochemical analysis was also performed 48, 60, and 72 hr postinject
ion in athymic nude rats. All animals demonstrated extensive endochondral b
one formation at the Ad-BMP-9 treatment sites within 3 weeks. The Sprague-D
awley rats also exhibited a massive, acute inflammatory infiltrate during t
he first week. Proliferating mesenchymal stem cells were clearly evident as
early as 2 days after treatment, which differentiated into small or hypert
rophied chondrocytes during the next week. During the third week, the carti
laginous matrix mineralized and formed woven bone, which converted to lamel
lar bone by 3 months. No evidence of bone formation was demonstrated at the
Ad-beta -Gal injection sites in the athymic nude or Sprague-Dawley rats. I
n addition, no cellular proliferation was seen at the Ad-beta -Gal treatmen
t sites in the athymic nude animals as assessed by light microscopy and Brd
U immunohistochemistry. The extensive bone formation induced by Ad-BMP-9 su
ggests that BMP gene therapy may have potential utility in the treatment of
degenerative, rheumatic, or traumatic bone pathology.